The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents

Current Medicinal Chemistry

Volumn 18, Issue 33, 2011, Pages 5114-5144

  Secci, D ^a   Bolasco, A ^a   Chimenti, P ^a   Carradori, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Anticonvulsant agents; Antidepressant agents; Isocarboxazid; Monoamine oxidase; N thiocarbamoyl; Parkinson's disease; Porsolt's Test; Pyrazole; Pyrazolidine; Pyrazoline

Indexed keywords

ACETYLCHOLINESTERASE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENMOXIN; CLOMIPRAMINE; FLUOXETINE; FUNCTIONAL GROUP; HETEROCYCLIC COMPOUND; HYDRAZINE DERIVATIVE; IPROCLOZIDE; IPRONIAZID; ISOCARBOXAZID; MEBANAZINE; METFENDRAZINE; MONOAMINE OXIDASE INHIBITOR; NIALAMIDE; NITROGEN; OCTAMOXIN; PARGYLINE; PHENELZINE; PHENIPRAZINE; PHENOXYPROPAZINE; PIVHYDRAZINE; PYRAZOLE DERIVATIVE; PYRAZOLINE DERIVATIVE; RESERPINE; SAFRAZINE; TRANYLCYPROMINE; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; DRUG STRUCTURE; EMOTION; ENZYME ACTIVITY; LOCOMOTION; NEUROPSYCHIATRY; NONHUMAN; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054860498     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797636090     Document Type: Article

References (90)

1. Bach, A.W.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDna cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA, 1988, 85, 4934-4938
2. Edmondson, D.E.; Binda, C.; Wang, J.; Upadhayay, A.K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry, 2009, 48, 4220-4230.
3. Tipton, K.F.; Boyce, S.; O'Sullivan, J.; Davey, G.P.; Healy, J. Monoamine oxidases: Certainties and uncertainties. Curr. Med. Chem., 2004, 11(15), 1965-1982. (Pubitemid 38967723)
4. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactivation: From pathophysiology to therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1527-1533.
5. Youdim, M.B.H.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309.
6. Cesura, A.M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res., 1992, 38, 171-297.
7. Fowler, C.J.; Wiberg, A.; Oreland, L.; Marcusson, J.; Winblad, B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J. Neural Transm., 1980, 49, 1-20. (Pubitemid 10030548)
8. Strolin Benedetti, M.; Dostert, P. Monoamine oxidase, brain ageing and degenerative diseases. Biochem. Pharmacol., 1989, 38, 555-561. (Pubitemid 19050093)
9. Saura, J.; Andres, N.; Andrade, C.; Ojuel, J.; Eriksson, K.; Mahy, N. Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol. Aging, 1997, 18, 497-507. (Pubitemid 27497146)
10. Gardner, D.M.; Shulman, K.I.; Walker, S.E; Tailor, S.A. The making of a use friendly MAOI diet. J. Clin. Psychiat., 1996, 57, 99-104. (Pubitemid 26091470)
11. Bolasco, A.; Fioravanti, R.; Carradori, S. Recent development of monoamine oxidase inhibitors. Expert Opin. Ther. Patents, 2005, 15(12), 1763-1782. (Pubitemid 43056413)
12. Bolasco, A.; Carradori, S.; Fioravanti, R. Focusing on new monoamine oxidase inhibitors. Expert Opin. Ther. Patents, 2010, 20(7), 909-939.
13. Wouters, J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr. Med. Chem., 1998, 5(2), 137-162. (Pubitemid 28183854)
14. López-Muñoz, F.; Alamo, C. Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des., 2009, 15(14), 1559-1562.
15. Parmar, S.S.; Pandey, B.R.; Dwivedi, C.; Harbison, R.D. Anticonvulsant activity and monoamine oxidase inhibitory properties of 1,3,5-trisubstituted pyrazolines. J. Pharm. Sci., 1974, 63, 1152-1155;
16. Soni, N.; Pande, K.; Kalsi, R.; Kupta, K.T.; Parmar, S.S.; Barthwal, J.P. Inhibition of rat brain monoamine oxidase and succinic dehydrogenase by anticonvulsant pyrazolines. Res. Commun. Chem. Pathol. Pharmacol., 1987, 56(1), 129-132. (Pubitemid 17066776)
17. Kameyama, T.; Nabeshima, T.; Yoshida, N.; Yamaguchi, K. Neurochemical studies of an analgesic, 1,3-diphenyl-5-(2-dimethylaminopropionamide)- pyrazole. Res. Commun. Chem. Pathol. Pharmacol., 1981, 31(1), 31-53. (Pubitemid 11173793)
18. Krueger, M.J.; Mazouz, F.; Ramsay, R.R.; Milcent, R.; Singer, T.P. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun., 1995, 206, 556-562.
19. Hubálek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmonson, D.E. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase. J. Biol. Chem., 2005, 280, 15761-15766. (Pubitemid 40616695)
20. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Legnetti, F.; Catto, M.; Carrupt, P.A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem., 2006, 49, 6264-6272. (Pubitemid 44595203)
21. Fustero, S.; Simón-Fuentes, A.; Sanz-Cervera, J.F. Recent advances in the synthesis of pyrazoles. A review. Org. Prep. Proced. Int., 2009, 41(4), 253-290;
22. Wiley, R.H.; Behr, L.C.; Fusco, R.; Jarboe, C.H. The Chemistry of Heterocyclic Compounds: Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings; John Wiley & Sons, Ltd: New York, 1967.
23. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Befani, O.; Turini, P.; Ortuso, F.; Alcaro, S. Monoamine oxidase isoformdependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors. J. Med. Chem., 2007, 50, 425-428. (Pubitemid 46239776)
24. Elguero, J. In: Comprehensive Heterocyclic Chemistry; Pergamon: Oxford, 1996.
25. Kumar, S.; Bawa, S.; Drabu, S.; Kumar, R.; Gupta, H. Biological activities of pyrazoline derivatives - A recent development. Recent Patents on Anti-Infect. Drug Discov., 2009, 4, 154-163.
26. Gökhan, N.; Yeşilada, A.; Uçar, G.; Erol, K.; Bilgin, A.A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and evaluation as MAO inhibitors. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 362-371. (Pubitemid 37127992)
27. Yabanoǧlu, S.; Uçar, G.; Gökhan, N.; Salgin, U.; Yeşilada, A.; Bilgin, A.A. Interaction of rat lung SSAO with the novel 1-N-substituted thiocarbamoyl- 3-substituted phenyl-5-(2-pyrrolyl)-2-pyrazoline derivatives. J. Neural. Transm., 2007, 114, 769-773.
28. Millard, C.B.; Broomfield, C.A. Anticholinesterases: Medical applications of neurochemical principles, J. Neurochem., 1995, 64, 1909-1918;
29. Giacobini, E. Selective inhibitors of butyrylcholinesterase: A valid alternative for theraphy of Alzheimer's disease? Drugs Aging, 2001, 18, 891-898. (Pubitemid 34275750)
30. Taha, A.M.; Omar, N.M.; Bayomi, S.M.; Ammar, E.M.; Afifi, A. Synthesis and screening of cyclic benzylhydrazine congeners as antidepressants. J. Pharm. Sci., 1974, 63(3), 395-398.
31. Maryanoff, B.E.; McComsey, D.F.; Costanzo, M.J.; Setler, P.E.; Gardocki, J.F.; Shank, R.P.; Schneider, C.R. Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J. Med. Chem., 1984, 27, 946-947.
32. Bilgin, A.A.; Yeşilada, A.; Palaska, E.; Sunal, R. Synthesis and antidepressant activity of some new 8-thiocarbamoyl-7,8- diazabicyclo[4.3.0]non- 6-ene derivatives. Arzneim.-Forsch./Drug Res., 1992, 42(11), 1271-1273.
33. Bilgin, A.A.; Palaska, E.; Sunal, R. Studies on the synthesis and antidepressant activity of some 1-thiocarbamoyl-3,5-diphenyl- 2-pyrazolines. Arzneim.-Forsch./Drug Res., 1993, 43, 1041-1044. (Pubitemid 23311876)
34. Ruhoǧlu, O.; Özdemir, Z.; Çaliş, Ü.; Gümüşel, B.; Bilgin, A.A. Synthesis of and pharmacological studies on the antidepressant and anticonvulsant activities of some 1,3,5-trisubstituted pyrazolines. Arzneim.-Forsch., 2005, 55(8), 431-436. (Pubitemid 41190744)
35. Özdemir, Z.; Kandilci, H.B.; Gümüşel, B.; Çaliş, Ü.; Bilgin, A.A. Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. Eur. J. Med. Chem., 2007, 42(3), 373-379. (Pubitemid 46349364)
36. Porsolt, R.D.; LePichon, M.; Jaifre, M. Depression: A new animal model sensitive to antidepressant treatments. Nature, 1977, 266, 730-732. (Pubitemid 8073804)
37. Palaska, E.; Erol, D.; Demirdamar, R. Synthesis and antidepressant activities of some 1,3,5-triphenyl-2-pyrazolines. Eur. J. Med. Chem., 1996, 31, 43-47. (Pubitemid 26037819)
38. Palaska, E.; Aytemir, M.; Uzbay, I.T.; Erol, D. Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines. Eur. J. Med. Chem., 2001, 36, 539-543. (Pubitemid 32781717)
39. Prasad, Y.R.; Rao, A.L.; Prasoona, L.; Murali, K.; Kumar, P.R. Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2β- hydroxy naphthalen-1β-yl)-1,5-diphenyl-2-pyrazolines. Bioorg. Med. Chem. Lett., 2005, 15, 5030-5034. (Pubitemid 41400179)
40. Tabarelli, Z.; Rubin, M.A.; Berlese, D.B.; Sauzem, P.D.; Missio, T.P.; Teixeira, M.V.; Sinhorin, A.P.; Martins, M.A.P.; Zanatta, N.; Bonacorso, H.G.; Mello, C.F. Antinociceptive effect of novel pyrazolines in mice. Brazilian J. Med. Biol. Res., 2004, 37, 1531-1540. (Pubitemid 39369041)
41. Can, Ö.D.; Özkay, Ü.D.; Kaplancikli, Z.A.; Öztürk, Y. Effects of some 1,3,5- trisubstitued-2-pyrazoline derivatives on depression and anxiety parameters of mice. Arch. Pharm. Res., 2009, 32(9), 1293-1299.
42. Tanaka, M.; Telegdy, G. Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull., 2008, 77(5), 301-305.
43. Katz, R.J. Animal models and human depressive disorders. Neurosci. Biobehav. Rev., 1981, 5, 231-246. (Pubitemid 11074537)
44. Cryan, J.F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol. Sci., 2002, 23(5), 238-245. (Pubitemid 34465544)
45. Kaplancikli, Z.A.; Turan-Zitouni, G.; Özdemir, A.; Can, Ö.D.; Chevallet, P. Synthesis and antinociceptive activities of some pyrazoline derivatives. Eur. J. Med. Chem., 2009, 44, 2606-2610.
46. Gok, S.; Demet, M.M.; Özdemir, A.; Turan-Zitouni, G. Evaluation of antidepressant-like effect of 2-pyrazoline derivatives. Med. Chem. Res., 2010, 19, 94-101.
47. Amnerkar, N.D.; Bhusari, K.P. Synthesis, anticonvulsant activity and 3DQSAR study of some prop-2-eneamido and 1-acetyl-pyrazolin derivatives of aminobenzothiazole. Eur. J. Med. Chem., 2010, 45(1), 149-159.
48. Siddiqui, A.A.; Rahman, A.Md.; Shaharyar, Md.; Mishra, R. Synthesis and anticonvulsant activity of some substituted 3,5-diphenyl-2-pyrazoline-1- carboxamide derivatives. Chem. Sci. J., 2010, CSJ-8.
49. Reyes-Parada, M.; Fierro, A.; Iturriaga-Vásquez, P.; Cassels, B.K. Monoamine oxidase inhibition in the light of new structural data. Curr. Enzyme Inhib., 2005, 1, 85-95.
50. Manna, F.; Chimenti, F.; Bolasco, A.; Bizzarri, B.; Befani, O.; Pietrangeli, P.; Mondovi, B.; Turini, P. Inhibitory effect of 1,3,5-triphenyl-4,5-dihydro- (1H)-pyrazole derivatives on activity of amine oxidases. J. Enzyme Inhib., 1998, 13, 207-216. (Pubitemid 28230684)
51. Manna, F.; Chimenti, F.; Bolasco, A.; Bizzarri, B.; Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B. Selective inhibition of FAD and copperdependent amine oxidases by N-acetyl pyrazole derivatives. Inflamm. Res., 2001, 50, 128-129.
52. Manna, F.; Chimenti, F.; Bolasco, A.; Secci, D.; Bizzarri, B.; Befani, O.; Turini, P.; Mondovi, B.; Alcaro, S.; Tafi, A. Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorg. Med. Chem. Lett., 2002, 12, 3629-3633. (Pubitemid 35346503)
53. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B.; Cirilli, R.; La Torre, F. Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)- pyrazole derivatives against monoamine oxidase. J. Med. Chem., 2004, 47, 2071-2074. (Pubitemid 38453922)
54. Cirilli, R.; Ferretti, R.; Gallinella, B.; Turchetto, L.; Bolasco, A.; Secci, D.; Chimenti, P.; Pierini, M.; Fares, V.; Befani, O.; La Torre, F. Enantiomers of C5-chiral 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives: Analytical and semipreparative HPLC separation, chiroptical properties, absolute configuration, and inhibitory activity against monoamine oxidase. Chirality, 2004, 16, 625-636. (Pubitemid 39425821)
55. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Synthesis and molecular modelling of novel substituted-4,5- dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors. Chem. Biol. Drug Des., 2006, 67, 206-214.
56. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted- 4,5- dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem., 2006, 13, 1411-1428.
57. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Rossi, F.; Turini, P.; Ortuso, F.; Alcaro, S.; Cardia, M.C. Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Eur. J. Med. Chem., 2008, 43, 2262-2267.
58. Walter, W.; Voss, J. In The Chemistry of Amides; Zabicky, J. Ed.; Wiley and Sons: London, 1970.
59. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cirilli, R.; La Torre, F.; Cardia, M.C.; Distinto, S. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl- 3,5-diaryl-4,5-dihydro-(1H)-pyrazole derivatives. J. Med. Chem., 2005, 48, 7113-7122. (Pubitemid 41743625)
60. Cirilli, R.; Simonelli, A.; Ferretti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Maccioni, E.; La Torre, F. Analytical and semipreparative high performance liquid chromatography enantioseparation of new substituted 1- thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazoles on polysaccharidebased chiral stationary phases in normal-phase, polar organic and reversedphase conditions. J. Chromatogr. A, 2006, 1101, 198-203. (Pubitemid 41785550)
61. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A.; Yáñez, M.; Orallo, F. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5- di(hetero)aryl- 4,5-dihydro-(1H)-pyrazole derivatives. Eur. J. Med. Chem., 2010, 45, 800-804.
62. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis- and transresveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun., 2006, 344, 688-695.
63. Palaska, E.; Aydin, F.; Uçar, G.; Erol, D. Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro- 1Hpyrazole derivatives. Arch. Pharm. Chem. Life Sci., 2008, 341, 209-215.
64. Fioravanti, R.; Bolasco, A.; Manna, F.; Rossi, F.; Orallo, F.; Yáñez, M.; Vitali, A.; Ortuso, F.; Alcaro, S. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6479-6482.
65. Nishimura, R.; Tabata, K.; Arakawa, M.; Ito, Y.; Kimura, Y.; Akihisa, T.; Nagai, H.; Sakuma, A.; Kohno, H.; Suzuki, T. Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol. Pharm. Bull., 2007, 30, 1878-1883. (Pubitemid 47607775)
66. Pellow, S.; Chopin, P.; File, S.E.; Briley, M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 1985, 14, 149-167. (Pubitemid 16239568)
67. Uçar, G.; Gökhan, N.; Yeşilada, A.; Bilgin, A.A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci. Lett., 2005, 382, 327-331.
68. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51(3), 347-372. (Pubitemid 351252260)
69. Gökhan-Kelekçi, N.; Yabanoǧlu, S.; Küpeli, E.; Salgin, U.; Özgen, Ö.; Uçar, G.; Yeşilada, E.; Kendi, E.; Yeşilada, A.; Bilgin, A.A. A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg. Med. Chem., 2007, 15, 5775-5786. (Pubitemid 47043476)
70. Bekhit, A.A.; Hymete, A.; Bekhit, E.-D.A.A.; Damtew, A.; Aboul-Enein, Y.H. Pyrazoles as promising scaffold for the synthesis of anti-inflammatory and/or antimicrobial agent: A review. Mini-Rev. Med. Chem., 2010, 10(11), 1014-1033.
71. Okun, R.; Liddon, S.C.; Lasagnal, L. The effect of aggregation, electric shock and adrenergic blocking drugs on inhibition of the "Writhing Syndrome". J. Pharmacol. Exp. Ther., 1963, 139, 107-114.
72. Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C.; Distinto, S.; Costa, G.; Yáñez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D. Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Eur. J. Med. Chem., 2010, 45, 4490-4498.
73. Jayaprakash, V.; Sinha, B.N.; Uçar, G.; Ercan, A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6362-6368.
74. Jayaprakash, V.; Yabanoǧlu, S.; Sinha, B.N.; Uçar, G. Pyrazoline-based mycobactin analogues as dual inhibitors of MAO/cholinesterase. Turk. J. Biochem., 2010, 35(2), 91-98.
75. Ellman, G.L.; Courtney, K.D.; Andres, Jr V.; Featherstone, R.M. A new and rapid colorimetric determination of acetyl cholinesterase activity. Biochem. Pharmacol., 1961, 7(2), 88-95.
76. Karuppasamy, M.; Mahapatra, M.; Yabanoǧlu, S.; Uçar, G.; Sinha, B.N.; Basu, A.; Mishra, N.; Sharon, A.; Kulandaivelu, U.; Jayaprakash, V. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem., 2010, 18, 1875-1881.
77. Holt, A.; Sharman, D.F.; Baker, G.B.; Pelcic, M.M. Continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal. Biochem., 1997, 244, 384-392. (Pubitemid 27043336)
78. Sahoo, A.; Yabanoǧlu, S.; Sinha, B.N.; Uçar, G.; Basu, A.; Jayaprakash, V. Towards development of selective and reversible pyrazoline based MAOinhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem. Lett., 2010, 20, 132-136.
79. Tripathi, S.; Pandey, B.R.; Barthwal, J.P.; Kishor, K.; Bhargava, K.P. Novel indolylpyrazolines as monoamine oxidase inhibitors. Indian J. Physiol. Pharmacol., 1980, 24(2), 155-159. (Pubitemid 10013562)
80. Gökhan-Kelekçi, N.; Koyunoǧlu, S.; Yabanoǧlu, S.; Yelekçi, K.; Ǒzgen, O.; Uçar, G.; Erol, K.; Kendi, E.; Yeşilada, A. New pyrazoline bearing 4(3H)- quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. Bioorg. Med. Chem., 2009, 17, 675-689.
81. Lata, A.; Satsangi, R.K.; Srivastava, V.K.; Kishor, K. Monoamine oxidase inhibitory and CNS activities of some quinazolinones. Arzneim.-Forsch., 1982, 32(1), 24-27. (Pubitemid 12213321)
82. Shrimali, M.; Kalsi, R.; Dixit, K.S.; Barthwal, J.P. Substituted quinazolones as potent anticonvulsants and enzyme inhibitors. Arzneim.-Forsch., 1991, 41(5), 514-519.
83. Aboul-Enein, M.N. Synthesis of some pyrazolidine and Nphenylpyrazolidine derivatives. Promotionsarbeiten, 1965, 1963(3296), 1-65.
84. Omar, N.M.; Bayomi, S.M.; Taha, A.M. Synthesis of certain cyclic hydrazine derivatives as potential monoamine oxidase inhibitors. Egyptian J. Pharm. Sci. 1975, 16(1), 49-56. (Pubitemid 8049094)
85. Bayer Pharmaceuticals Corp. Pyrazole derivatives for the treatment of psychiatric disorders. WO2006060201, June 8, 2006.
86. Matsumoto, T.; Suzuki, O.; Furuta, T.; Asai, M.; Kurokawa, Y.; Nimura, Y.; Katsumata, Y.; Takahashi, I. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin. Biochem., 1985, 18, 126-129. (Pubitemid 15009688)
87. Helicon Therapeutics, Inc. Preparation of substituted pyrazoles as MAO-B inhibitors. US2007203154, August 30, 2007.
88. Harkcom, W.T.; Bevan, D.R. Molecular docking of inhibitors into monoamine oxidase B. Biochem. Biophys. Res. Commun., 2007, 360, 401-406. (Pubitemid 47030358)
89. Lecci, A.; Borsini, F.; Volterra, G.; Meli, A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology, 1990, 101, 255-261. (Pubitemid 20140228)
90. Griebel, G.; Perrault, G.; Sanger, D.J. Behavioral profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology, 1997, 131, 180-186. (Pubitemid 27261607)